Show simple item record

dc.contributor.authorDyason, Jeffreyen_US
dc.contributor.authorvon Itzstein, Marken_US
dc.date.accessioned2017-05-03T13:32:50Z
dc.date.available2017-05-03T13:32:50Z
dc.date.issued2001en_US
dc.identifier.issn00049425en_US
dc.identifier.urihttp://hdl.handle.net/10072/3678
dc.description.abstractThis review will give an overview of the design process behind the development of sialidase inhibitors, which can be used as anti-influenza drugs. Two drugs (Relenza頡nd Tamiflu驠are already available as prescription drugs and a third (BCX-1812) is currently undergoing third-phase clinical trials. Also, the use of molecular-modelling techniques in the understanding of the mechanism and the prediction of inhibition of this enzyme is reviewed.en_US
dc.description.peerreviewedYesen_US
dc.description.publicationstatusYesen_US
dc.languageEnglishen_US
dc.language.isoen_US
dc.publisherCSIRO Publishingen_US
dc.publisher.placeAustraliaen_US
dc.publisher.urihttp://www.publish.csiro.au/nid/51/paper/CH01173.htmen_US
dc.relation.ispartofpagefrom663en_US
dc.relation.ispartofpageto670en_US
dc.relation.ispartofissue11en_US
dc.relation.ispartofjournalAustralian Journal of Chemistryen_US
dc.relation.ispartofvolume54en_US
dc.subject.fieldofresearchcode250301en_US
dc.titleAnti-Influenza virus drug design: Sialidase inhibitorsen_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Peer Reviewed (HERDC)en_US
dc.type.codeC - Journal Articlesen_US
gro.date.issued2015-05-21T02:34:07Z
gro.hasfulltextNo Full Text


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record